Dihexa: The Synaptogenesis Accelerator
Last updated: March 2026
Dihexa (PNB-0408) is a synthetic hexapeptide HGF mimetic that activates the c-Met receptor pathway — the same system that drives synaptic formation in brain development. Animal studies show extraordinary in vitro potency. Zero human clinical trials. High-controversy, high-search-interest research compound.
🧪 Buy Dihexa at Swiss Chems →in vitro synaptogenesis (EC50)
published as of 2026
for Alzheimer's & Parkinson's
📋 On this page
Evidence Tier: Animal Only. Every Dihexa efficacy claim originates from rat studies and cell cultures. There are no published human clinical trials for Dihexa (PNB-0408) anywhere in the world. The "millions of times more potent than BDNF" figure is an in vitro binding affinity measurement — not a clinical potency comparison. Human pharmacokinetics, effective dosing, and long-term safety are completely unknown. This page presents what the animal literature shows — not a clinical endorsement.
How Dihexa Works
Dihexa operates by mimicking hepatocyte growth factor (HGF) — a pleiotropic cytokine that activates the c-Met tyrosine kinase receptor. In the brain, HGF/c-Met signaling is a master regulator of synaptogenesis, neuronal survival, and synaptic plasticity.
Dihexa is a small hexapeptide derived from angiotensin IV (N-hexanoic-Tyr-Ile-[6]-aminohexanoic amide). It functions as a hepatocyte growth factor (HGF) mimetic — binding to c-Met (the HGF receptor) and activating downstream signaling cascades including PI3K/Akt and MAPK/ERK pathways. These pathways are central to neuronal survival, synapse formation, and long-term potentiation (LTP), the cellular basis of memory.
The c-Met pathway promotes synaptogenesis — the formation of new synaptic connections between neurons. In preclinical work from the Harding lab (reviewed in Wright & Harding 2015), Dihexa was reported to induce dendritic arborization and increase synaptic spine markers in cultured and rodent hippocampal neurons, consistent with increased synaptic density. (Note: the primary 2014 behavioral paper from this group was later retracted — see citations.) HGF/c-Met-driven synaptogenesis is concentrated in hippocampal regions central to memory encoding. This is the proposed mechanism behind Dihexa's cognition-related effects in animal models.
The widely repeated "10 million times more potent than BDNF" figure originates from in vitro synaptogenesis assays in hippocampal cultures reported by the developing lab — a relative potency comparison at very low (sub-nanomolar to nanomolar) Dihexa concentrations versus much higher BDNF concentrations in the same assay. It is a binding/activation efficiency measure in isolated tissue, not a claim that Dihexa produces 10 million times more cognitive enhancement in humans. The exact figure traces to a single research group, has not been independently replicated, and in vitro potency rarely translates linearly to clinical efficacy. BDNF is itself highly restricted in human therapeutic use; comparing EC50s does not predict human outcomes.
Unlike most peptides, Dihexa was engineered to resist rapid degradation and cross the blood-brain barrier. Preclinical reports from the developing lab describe Dihexa retaining bioactivity after oral administration in rodent models and achieving CNS penetration — an unusual property for a peptide. This distinguishes it from larger peptides (like cerebrolysin) that require intravenous or subcutaneous injection. However, these are animal findings from a single research group, and human oral bioavailability data does not exist.
Dihexa was discovered in Dr. Joseph Harding's lab at Washington State University during research into angiotensin IV (Ang IV) — an active fragment of the renin-angiotensin system. Ang IV was found to have cognitive-enhancing properties mediated through an HGF-like mechanism. Dihexa is a synthetic analog optimized for stability and CNS penetration, stripping Ang IV's vasopressor activity while preserving the synaptogenic mechanism. This pharmaceutical design makes Dihexa conceptually distinct from other angiotensin peptides.
HGF/c-Met is a well-characterized oncogenic axis. Aberrant HGF/c-Met signaling drives tumor growth, angiogenesis, epithelial-mesenchymal transition (metastasis), and treatment resistance in gastric cancer, lung cancer, renal cell carcinoma, hepatocellular carcinoma, and glioblastoma. Multiple FDA-approved cancer drugs (capmatinib, tepotinib, crizotinib) are inhibitors of c-Met. Dihexa activates this axis — a meaningful oncogenic risk signal that has no published long-term data to either confirm or refute.
What the Animal Studies Show
The entire Dihexa evidence base is preclinical. The primary research comes from Dr. Joseph Harding's lab at Washington State University — essentially a single research group. This is a meaningful limitation: findings have not been independently replicated in multiple labs with different animal models, which is standard preclinical validation before human trials. The studies are real, published, and peer-reviewed — but they represent early-stage data, not a clinical evidence base.
The Fosgonimeton Connection
The most compelling indirect signal that HGF/c-Met activation may have therapeutic merit is the existence of pharmaceutical programs targeting the same pathway.
Fosgonimeton (ATH-1017) is a phosphate prodrug version of a Dihexa-related HGF/c-Met pathway activator. It was originally developed by Athira Pharma, which has since been rebranded as Quince Therapeutics. The compound converts to its active form in the body and targets the same c-Met mechanism as Dihexa, though as distinct molecules the two should not be conflated.
Phase 1: Fosgonimeton was well-tolerated in early-phase human testing and achieved target plasma concentrations, clearing the initial safety bar. This represented the first human pharmacokinetic data for the HGF/c-Met activator class.
Phase 2 — Mixed Picture: Phase 2 trials in Alzheimer's disease and Parkinson's disease dementia produced mixed results. Biomarker improvements appeared in subgroups of patients, but the primary cognitive endpoint did not reach statistical significance across the full study population. Quince Therapeutics is now refining patient selection criteria — looking for subgroups where the pathway activation is most likely to be clinically meaningful — ahead of future trials.
Interpretation: The Phase 2 stumble doesn't invalidate the mechanism — many drugs show subgroup signals before the field learns which patients actually respond. But it does temper the optimism that surrounded earlier Phase 1 results. The HGF/c-Met pathway remains a legitimate therapeutic target; translating that into consistent cognitive benefit in humans is proving harder than preclinical data suggested.
An important finding that often gets buried in the biohacker hype: animal research shows that Dihexa did not improve cognition in rats with normal cognitive function. The observed benefits — memory improvement, social recognition, maze performance — were specific to impairment models (such as scopolamine-induced deficits). Healthy-brain animals showed no measurable enhancement.
This positions Dihexa as a potential restorative agent in cognitive impairment — not a general enhancer for people with normal baseline cognition. If you're a healthy adult hoping for a cognitive edge, the animal data doesn't actually support that expectation. This distinction matters significantly for how Dihexa is being evaluated in clinical contexts.
| Feature | Dihexa (PNB-0408) | Fosgonimeton (ATH-1017) |
|---|---|---|
| Molecule type | Hexapeptide | Small molecule |
| Primary mechanism | HGF mimetic / c-Met activator | c-Met activator (allosteric) |
| Route (studied) | Oral (rats); intranasal (anecdotal) | Subcutaneous injection |
| Human trials | None published | Phase 2 (Alzheimer's, Parkinson's) |
| Regulatory status | Research chemical | IND (Investigational New Drug) |
| Safety data (humans) | None | Phase 2 cohort data available |
| Can extrapolate to other | NO — different molecules, different profiles | |
The Cancer Risk — Read This First
HGF/c-Met is an oncogenic pathway. This is not a theoretical or minor concern — it is a well-documented oncogenic signaling axis. Multiple FDA-approved cancer drugs are HGF/c-Met inhibitors (capmatinib, tepotinib, crizotinib). Dihexa activates this pathway. Anyone with a personal or family history of cancer, or high cancer risk factors, should treat this as a serious contraindication.
Aberrant HGF/c-Met signaling is implicated in gastric cancer (MET amplification), non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, and glioblastoma multiforme. The pathway drives tumor cell proliferation, survival, angiogenesis (blood supply to tumors), and invasion/metastasis. The FDA has approved c-Met inhibitors as cancer treatments precisely because this axis is so oncogenically potent.
The oncogenic risk from short-term HGF/c-Met activation at nootropic doses is entirely unknown. No animal carcinogenicity studies with Dihexa have been published. Standard drug development would require multi-year rodent carcinogenicity studies before human trials — these have not been conducted or published. The risk could be low, moderate, or high — there is simply no data.
Endogenous HGF/c-Met signaling occurs naturally in healthy brain development and injury repair. The concern is not that any c-Met activation causes cancer — it's that sustained, pharmacological upregulation of this axis beyond normal physiological ranges carries unknown long-term risk, particularly in peripheral tissues (liver, lung, kidney) where c-Met overactivation is clearly oncogenic.
Athira Pharma's fosgonimeton Phase 2 trials did not report significantly elevated cancer adverse events during the trial period. However, Phase 2 trials are short-term (months), use carefully selected patients, and are not designed to detect long-latency carcinogenesis. A clean short-term Phase 2 safety record does not rule out cancer risk with years of use — and again, fosgonimeton ≠ Dihexa.
⛔ Absolute Contraindications (Based on Mechanism)
- ✗Personal history of any cancer (especially MET-driven: gastric, lung, renal, liver)
- ✗Strong family history of cancer (first-degree relatives)
- ✗Pre-existing elevated liver enzymes or liver disease
- ✗Pregnancy or attempting pregnancy
- ✗Children or adolescents (developing brain/HGF system)
- ✗Anyone not willing to accept unknown risk with no human safety data
Who Is Dihexa For — With Honest Caveats
The honest answer: Dihexa is a research compound for investigators who understand they are self-experimenting with a molecule that has zero human safety or efficacy data. It is not a safe nootropic. It is not a validated cognitive enhancer. It is a compound of theoretical interest derived from preclinical evidence that may or may not translate to humans. Anyone considering it must fully accept these conditions.
✓ Profile Where Research May Apply
- Adult (40+) with documented cognitive impairment and no cancer history — the animal data is specific to impairment, not healthy baseline enhancement
- Has read and fully understands the HGF/c-Met oncogenic risk, and accepts the unknown
- Has consulted a physician who understands the mechanism and associated risks
- Interested in the synaptogenesis angle — neuroplasticity, synapse repair, impairment recovery
- Has first exhausted well-evidenced interventions (lion's mane, bacopa, semax, cerebrolysin)
- Has had baseline cancer screening (bloodwork, imaging appropriate for age/risk) before starting
- Using topical application and short-cycle protocols, cycled with Semax, Selank, or Cerebrolysin — not run continuously or as a standalone compound
✗ This Research Does NOT Apply If You...
- Have a personal or family cancer history — the HGF/c-Met risk is not theoretical
- Want a "safe" or "proven" nootropic — Dihexa is neither
- Are under 30 — your HGF system is already robustly active; uncontrolled activation is higher risk
- Expect human-equivalent efficacy from rat data — preclinical results frequently fail in humans
- Haven't tried lower-risk synaptogenesis/BDNF approaches (lion's mane, semax, exercise protocols)
- Are unwilling to get regular bloodwork and liver function monitoring
- Source from unverified research chemical vendors with unknown purity
Primary Research Sources
Key Takeaways
- Activates HGF/c-Met pathway — a real and well-characterized synaptogenesis mechanism
- Extraordinary in vitro potency at synaptogenesis EC50 (~10 million× BDNF in cell culture)
- Reported to reverse scopolamine memory deficits in rodents — but the key 2014 behavioral paper was retracted (2025); treat as unconfirmed
- Oral bioavailability and CNS penetration demonstrated in rat models
- Fosgonimeton (different molecule, same pathway) — Phase 1 cleared safety; Phase 2 mixed (biomarker signals but primary endpoint missed; Quince Therapeutics refining patient selection)
- HGF/c-Met is a validated therapeutic target — serious pharma is pursuing it
- Developed by a legitimate academic lab at a R1 university (WSU)
- Does NOT improve cognition in animals with normal baseline — benefits are specific to impairment models
- No human clinical trials — zero Phase 1, 2, or 3 data for Dihexa itself
- "10 million times more potent than BDNF" is an in vitro EC50 — not clinical potency
- Human pharmacokinetics, bioavailability, and optimal dosing are completely unknown
- Long-term oncogenic risk of sustained HGF/c-Met activation in humans
- Whether rat impairment-model results translate to human cognitive benefit in actual disease
- Research primarily from a single lab group — limited independent replication
- Fosgonimeton's mixed Phase 2 data cannot be extrapolated to Dihexa in either direction
- Interaction profile with other nootropics, drugs, or existing cancers
Related Compounds & Resources
🛒 Recommended Products
Supplements and tools for cognitive health and the serious nootropic researcher.
Affiliate links help support HighPeptides at no extra cost to you.
Research-Grade Peptides
Third-party tested compounds with certificates of analysis. Used by researchers worldwide.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
Dihexa is NOT approved for human use anywhere in the world. It has never been studied in human clinical trials. This page is for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The cancer risk section is not hypothetical — the HGF/c-Met pathway is a validated oncogenic axis. Do not use this information to make decisions about your health without consulting a qualified healthcare provider who understands the mechanism. Animal Data OnlyNo Human TrialsRelated Pathway: Phase 2